glp 1 drug classification Glucagon-like peptide-1 A schematic overview of GLP-1

Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself

Macular Edema: Poorly controlled diabetes can cause fluid leakage into the macula (the central part of the retina responsible for detailed vision)

Image Credit: Alexander_P / Shutterstock In a recent commentary article published in the journal Cell Reports Medicine , authors Maria J

Given she was then just 30 years old and was one of the youngest scientists in her division this was highly daunting

Hadidchi emphasizes that this dual action helps patients feel fuller with smaller portions and reduces hunger, aiding in adherence to a lower-calorie diet

[49] observed significant reduction in hs-CRP with twice-daily exenatide, and DURATION-2, DURATION-3, DURATION-3 extension, and DURATION-5 studies observed considerable reductions in inflammatory markers such as hs-CRP or CRP (Table 2) [484950515253545556575859606162636465666768697071727374757677787980818283848586]